Tagraxofusp
CD123 Antibody Toxin Congregate (CD123 ATC; Tagraxofusp) Combined With Azacitidine for Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for Patients With CD123-Positive Malignant
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 43 patients (estimated)
- Sponsors
- City of Hope Medical Center
- Collaborators
- National Cancer Institute (NCI)
- Tags
- CD123, Post-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 1 day ago
- SparkCures ID
- 2015
- NCT Identifier
- NCT06498973
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.